Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study

dc.contributor.author
Cornely, Oliver A.
dc.contributor.author
Cisneros, José M.
dc.contributor.author
Torre-Cisneros, Julian
dc.contributor.author
Rodríguez-Hernández, María Jesús
dc.contributor.author
Tallón-Aguilar, Luis
dc.contributor.author
Calbo, Esther
dc.contributor.author
Horcajada Gallego, Juan Pablo
dc.contributor.author
Queckenberg, Christian
dc.contributor.author
Zettelmeyer, Ulrike
dc.contributor.author
Arenz, Dorothee
dc.contributor.author
Rosso-Fernández, Clara M.
dc.contributor.author
Jiménez-Jorge, Silvia
dc.contributor.author
Turner, Guy
dc.contributor.author
Raber, Susan
dc.contributor.author
O'Brien, Seamus
dc.contributor.author
Luckey, Alison
dc.contributor.author
COMBACTE-CARE consortium/REJUVENATE Study Group
dc.date.issued
2020-06-09T06:47:52Z
dc.date.issued
2020-06-09T06:47:52Z
dc.date.issued
2020
dc.identifier
Cornely OA, Cisneros JM, Torre-Cisneros J, Rodríguez-Hernández MJ, Tallón-Aguilar L, Calbo E, et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020 Mar 1; 75(3):618-27. DOI: 10.1093/jac/dkz497
dc.identifier
0305-7453
dc.identifier
http://hdl.handle.net/10230/44937
dc.identifier
http://dx.doi.org/10.1093/jac/dkz497
dc.description.abstract
Objectives: To investigate pharmacokinetics (PK) and safety (primary objectives) and efficacy (secondary objective) of the investigational monobactam/β-lactamase inhibitor combination aztreonam/avibactam in patients with complicated intra-abdominal infection (cIAI). Methods: This Phase 2a open-label, multicentre study (NCT02655419; EudraCT 2015-002726-39) enrolled adults with cIAI into sequential cohorts for 5-14 days treatment. Cohort 1 patients received an aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h; Cohort 2 received 500/167 mg (30 min infusion), followed by 1500/500 mg (3 h infusions) q6h. Cohort 3 was an extension of exposure at the higher dose regimen. Doses were adjusted for creatinine clearance of 31-50 mL/min (Cohorts 2 + 3). All patients received IV metronidazole 500 mg q8h. PK, safety and efficacy were assessed. Results: Thirty-four patients (Cohort 1, n = 16; Cohorts 2 + 3, n = 18) comprised the modified ITT (MITT) population. Mean exposures of aztreonam and avibactam in Cohorts 2 + 3 were consistent with those predicted to achieve joint PK/pharmacodynamic target attainment in >90% patients. Adverse events (AEs) were similar between cohorts. The most common AEs were hepatic enzyme increases [n = 9 (26.5%)] and diarrhoea [n = 5 (14.7%)]. Clinical cure rates at the test-of-cure visit overall were 20/34 (58.8%) (MITT) and 14/23 (60.9%) (microbiological-MITT population). Conclusions: Observed AEs were consistent with the known safety profile of aztreonam monotherapy, with no new safety concerns identified. These data support selection of the aztreonam/avibactam 500/167 mg (30 min infusion) loading dose and 1500/500 mg (3 h infusions) maintenance dose q6h regimen, in patients with creatinine clearance >50 mL/min, for the Phase 3 development programme.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Oxford University Press
dc.rights
Copyright © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Abdomen -- Malalties
dc.subject
Abdomen -- Infeccions -- Tractament
dc.title
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)